Results 311 to 320 of about 518,198 (339)

Cyclin-dependent kinase 5 (CDK5) inhibitors in Parkinson disease. [PDF]

J Cell Mol Med
Alrouji M, Al-Kuraishy HM, Al-Gareeb AI, Alshammari MS, Alexiou A, Papadakis M, Bahaa MM, Batiha GE.   +7 more
europepmc   +1 more source

Correction: Absence of cyclin-dependent kinase inhibitor p27 or p18 increases efficiency of iPSC generation without induction of iPSC genomic instability. [PDF]

Cell Death Dis
Zhan Z, Song L, Zhang W, Gu H, Cheng H, Zhang Y, Yang Y, Ji G, Feng H, Cheng T, Li Y.   +10 more
europepmc   +1 more source

Cyclin-dependent kinase-like 5 (CDKL5) binds to talin and is anchored at the postsynaptic density via direct interaction with PDZ domains

Otani Y, Goodall E, Srinivasan V, Ball NJ, Barnett SFH, Zech T, Saarikangas J, Goult BT.   +7 more
europepmc   +1 more source

18F-FLT PET, a Noninvasive Pharmacodynamic Biomarker of Tumor Cell Proliferation, Detected Differential Response to Various Cyclin-Dependent Kinase (CDK) Inhibitors. [PDF]

Mol Cancer Ther
Giddabasappa A, Jiang ZK, Yang B, Chen L, Liu F, Cabral E, Ram S, Boras B, Huser N, Zhang CC, Noorbehesht K, Manzuk LK, Visswanathan R, Mojtahedzadeh S, Affolter T, Carmody J, Kang AN, Petroski MD, Khamphavong PL, VanArsdale T, Nguyen QD, Maresca KP, Dann SG.   +22 more
europepmc   +1 more source

A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer. [PDF]

Front Oncol
Zhang J, Xu X, Zhou Y, Su J, Wang J.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.

Journal of Medicinal Chemistry, 2018
Cyclin-dependent kinase 2 (CDK2) drives the progression of cells into the S- and M-phases of the cell cycle. CDK2 activity is largely dispensable for normal development, but it is critically associated with tumor growth in multiple cancer types. Although
S. Tadesse, E. Caldon, W. Tilley, Shudong Wang   +3 more
semanticscholar   +1 more source

Venous thromboembolism in breast cancer patients receiving cyclin‐dependent kinase inhibitors

Journal of Thrombosis and Haemostasis, 2019
Venous thromboembolism (VTE) complicates several anticancer regimens including chemotherapy and antiangiogenic agents. Cyclin‐dependent kinase inhibitors (CDKIs) are a new approach for hormone receptor‐positive metastatic breast cancer (mBC).
Lorenzo Gervaso, A. Montero, X. Jia, A. Khorana   +3 more
semanticscholar   +1 more source

Cyclin‐Dependent Kinase 12, Immunity, and Prostate Cancer

New England Journal of Medicine, 2018
Prostate Cancer and Checkpoint Inhibition Somatic inactivating variants in the gene CDK12, encoding cyclin-dependent kinase 12, generate fusion-induced neoantigens in prostate cancer.
E. Antonarakis
semanticscholar   +1 more source

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

Molecular Cancer Therapeutics, 2004
PD 0332991 is a highly specific inhibitor of cyclin-dependent kinase 4 (Cdk4) (IC50, 0.011 micromol/L) and Cdk6 (IC50, 0.016 micromol/L), having no activity against a panel of 36 additional protein kinases.
D. W. Fry, P. Harvey, P. Keller, W. Elliott, M. Meade, E. Trachet, M. Albassam, Xianxian Zheng, W. Leopold, N. Pryer, P. Toogood   +10 more
semanticscholar   +1 more source